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Purpose: Undertake a systematic investigation into associations between genetic predictors of lipid fractions
and age-related macular degeneration (AMD) risk.
Design: Two-sample Mendelian randomization investigation using published data.
Participants: A total of 33 526 individuals (16 144 cases, 17 832 controls) predominantly of European
ancestry from the International Age-related Macular Degeneration Genomics Consortium.
Methods: We consider 185 variants previously demonstrated to be associated with at least 1 of low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides at a genome-wide level of
signiﬁcance, and test their associations with AMD. We particularly focus on variants in gene regions that are
proxies for speciﬁc pharmacologic agents for lipid therapy. We then conduct a 2-sample Mendelian randomi-
zation investigation to assess the causal roles of LDL-cholesterol, HDL-cholesterol, and triglycerides on AMD risk.
We also conduct parallel investigations for coronary artery disease (CAD) (viewed as a positive control) and
Alzheimer’s disease (a negative control) for comparison.
Main Outcome Measures: Diagnosis of AMD.
Results: We ﬁnd evidence that HDL-cholesterol is a causal risk factor for AMD, with an odds ratio (OR) estimate
of 1.22 (95% conﬁdence interval [CI], 1.03e1.44) per 1 standard deviation increase in HDL-cholesterol. No causal
effect of LDL-cholesterol or triglycerides was found. Variants in the CETP gene region associated with increased
circulating HDL-cholesterol also associate with increased AMD risk, although variants in the LIPC gene region that
increase circulating HDL-cholesterol have the opposite direction of association with AMD risk. Parallel analyses
suggest that lipids have a greater role for AMD compared with Alzheimer’s disease, but a lesser role than for CAD.
Conclusions: Some genetic evidence suggests that HDL-cholesterol is a causal risk factor for AMD risk and
that increasing HDL-cholesterol (particularly via CETP inhibition) will increase AMD risk. Ophthalmology 2017;-
:1e10 ª 2017 by the American Academy of Ophthalmology. This is an open access article under the CC BY li-
cense (http://creativecommons.org/licenses/by/4.0/).
Supplemental material available at www.aaojournal.org.Age-related macular degeneration (AMD) has one of the
longest histories of genetic discovery efforts of any disease in
the genome-wide association study era.1 To date, genetic
variants in 34 independent loci have been demonstrated to
be associated with AMD risk,2 highlighting several
biological mechanisms that provide insight into etiologic
processes and may suggest potential therapeutic targets.3
Several of the genetic variants associated with AMD risk
are located in gene regions that also have associations with
lipids or lipid-related biology, in particular the CETP, LIPC,
and APOE gene regions. Links between lipid deposition and
AMD have been hypothesized for more than 50 years.4 High-
density lipoprotein (HDL) cholesterol concentrations have
been shown to be positively associated with AMD risk in
observational studies, whereas low-density lipoprotein (LDL)ª 2017 by the American Academy of Ophthalmology
This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/). Published by Elsevier Inc.cholesterol and triglycerides generally have been found to be
negatively associated with risk.5e7 Previous investigators
have suggestedmechanistic links between atherosclerosis and
pathologic features of AMD, such as soft drusen and lipid
deposition in Bruch’s membrane, using information about the
function of lipid-related genetic variants associated with
AMD risk.8,9 However, links between genetic variants asso-
ciated with lipid fractions and AMD risk has not been sys-
tematically investigated.
Mendelian randomization is the use of genetic variants as
proxies for modiﬁable risk factors.10,11 A genetic variant
that has a speciﬁc association with a risk factor can be used
to assess the effect of long-term elevated levels of that risk
factor on a disease outcome. The approach exploits the
random allocation of genetic variants at meiosis, which1http://dx.doi.org/10.1016/j.ophtha.2017.03.042
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the population from potential confounders, and the ﬁxed
nature of genetic variants, which results in genetic associ-
ations being immune to the inﬂuences of environmental
factors and reverse causation. Mendelian randomization
investigations address the causal question: Do long-term
elevated levels of the risk factor lead to increased (or
decreased) risk of the disease outcome? Previous Mendelian
randomization analyses have suggested that LDL-
cholesterol is a causal risk factor for coronary artery dis-
ease (CAD) risk,12,13 but HDL-cholesterol is not.14
In this article, we apply a 2-sample Mendelian random-
ization approach15 to consider the effects of lipid fractions
on AMD risk using 185 genetic variants previously
demonstrated to be associated with at least 1 of LDL-
cholesterol, HDL-cholesterol, or triglycerides at a genome-
wide level of signiﬁcance. We consider the associations of
these variants with lipid fractions taken from the Global
Lipids Genetics Consortium on up to 188 577 individuals of
European ancestry16 and associations with AMD risk from
the International Age-related Macular Degeneration Geno-
mics Consortium on up to 33 526 individuals (16 144 cases,
17 832 controls) predominantly of European ancestry.2
The investigation consists of 4 related components. First,
we consider whether the 185 variants are more associated
with AMD risk than would be expected by chance alone and
highlight those variants associated with AMD risk at a
Bonferroni-corrected signiﬁcance threshold. Second, we
consider individual genetic variants in gene regions that are
proxies for speciﬁc pharmacologic agents that have been or
are being developed for lipid therapy. Third, we perform
univariable Mendelian randomization analyses for the ef-
fects of LDL-cholesterol, HDL-cholesterol, and tri-
glycerides on AMD risk, and undertake sensitivity analyses
using the MR-Egger17 and weighted median18 methods that
make weaker assumptions than those in a standard
Mendelian randomization analysis. Fourth, we perform a
multivariable Mendelian randomization analysis for the
effects of the lipid fractions on AMD risk.19 For part of
these analyses, we also test for heterogeneity in the
models to see whether genetic associations with AMD risk
vary more than would be expected on the basis of the
associations of the variants with the lipid fractions alone.
For a positive control, we also consider genetic associ-
ations with CAD risk, because lipid fractions are known to
inﬂuence CAD risk. For a negative control, we consider
genetic associations with Alzheimer’s disease risk, a disease
that has an age proﬁle of cases similar to AMD, but which is
not known to be linked to lipid fractions or lipid-related
variants20 (with the exception of variants in the APOE
gene region that are strong predictors of Alzheimer’s
disease21). In each analysis, we compare the genetic
associations and causal estimates obtained for AMD with
those for CAD and Alzheimer’s disease. Associations with
CAD risk are taken from the Coronary Artery Disease
Genome wide Replication and Meta-analysis plus Coro-
nary Artery Disease (CARDIoGRAMplusC4D) consortium
on up to 171 191 individuals (60 801 cases, 110 390 con-
trols) mostly of European ancestry.22 Associations with
Alzheimer’s disease risk are taken from the International2Genomics of Alzheimer’s Project consortium on up to
54 162 individuals (17 008 cases, 37 154 controls) of
European ancestry (discovery phase only).23Methods
All analyses were performed using R (version 3.3.1). All statistical
tests are 2 sided. This article used only publically available data
and thus did not require speciﬁc ethical approval. Ethical approval
for the original studies can be found in the original source articles.
This research adhered to the Declaration of Helsinki.Genetic Associations of Variants with Disease
Outcomes
Genetic associations with LDL-cholesterol, HDL-cholesterol, and
triglycerides were obtained from the Global Lipids Genetics
Consortium16; associations with AMD risk were obtained from the
International Age-related Macular Degeneration Genomics Con-
sortium2; associations with CAD risk were obtained from the
CARDIoGRAMplusC4D consortium22; and associations with
Alzheimer’s disease were obtained from the International
Genomics of Alzheimer’s Project.23 Associations with AMD risk
are for advanced AMD cases (deﬁned as “geographic atrophy or
choroidal neovascularization in at least 1 eye and age at ﬁrst
diagnosis 50 years”) versus controls (no advanced or
intermediate AMD; intermediate AMD is deﬁned as “pigmentary
changes in the retinal pigment epithelium [RPE] or more than 5
macular drusen greater than 63 mm in diameter and age at ﬁrst
diagnosis 50 years”).
Beta-coefﬁcients and standard errors for all variants are
available for download, except for the associations with AMD
risk. For these, we took the P values and directions of associa-
tions that are published by the International Age-related Macular
Degeneration Genomics Consortium (http://csg.sph.umich.edu/
abecasis/public/amd2015/), and converted the P values to z
scores. We used published association estimates (beta-co-
efﬁcients and standard errors) with AMD risk for the 34 genome-
wide signiﬁcant variants (see Table 1 in reference 2), and the
assumption that the standard error of the beta-coefﬁcient from a
logistic regression analysis is proportional to
1 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃMAFð1MAFÞp , where MAF is the minor allele frequency
(assuming that the sample size was the same for all variants).24
This means that the standard error multiplied byﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MAFð1MAFÞp should be constant for all variants. We took
the average value of this expression for the 34 genome-wide
signiﬁcant variants and divided by
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MAFð1MAFÞp to esti-
mate the standard errors for the remaining variants. We then
multiplied the estimated standard error by the published z score to
obtain the beta-coefﬁcient for each variant and used the published
direction of association to orientate this coefﬁcient.
To assess the validity of this approach, we repeated it ﬁrst
dividing the 34 variants for which beta-coefﬁcients are provided at
random into 2 equal groups of 17. We then found the average value
of the constant [standard error multiplied by
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MAFð1MAFÞp ]
using the ﬁrst 17 variants and used this to calculate the beta-
coefﬁcients for the associations of the remaining 17 variants. We
then compared the calculated values of the beta-coefﬁcients for
these variants with their values provided by the consortium. The
correlation between the calculated and actual values of the beta-
coefﬁcients was 0.993. This suggests that the approach was valid
and that the beta-coefﬁcients calculated for the 185 lipid-related
variants are close to the true values.
Table 1. Lipid-Related Genetic Variants Associated with Age-Related Macular Degeneration Risk at a Bonferroni-Corrected Level of
Signiﬁcance
Single Nucleotide
Polymorphism Nearest Gene
Association of Variant with. (Beta Coefﬁcient and P Value)
LDL-c HDL-c Triglycerides AMD Risk
rs1883025 (C) ABCA1 0.030, P ¼ 131011 0.070, P ¼ 631066 0.022, P ¼ 33108 0.104, P ¼ 2107
rs653178 (C) ATXN2 L0.023, P ¼ 23109 L0.026, P ¼ 131013 0.010, P ¼ 0.004 0.064, P ¼ 0.0002
rs1532085 (G) LIPC 0.003, P ¼ 0.48 L0.107, P ¼ 2310209 L0.031, P ¼ 531020 0.123, P ¼ 331012
rs261342 (C) LIPC 0.003, P ¼ 0.69 L0.107, P ¼6 31071 L0.045, P ¼ 431014 0.117, P ¼ 13109
rs9989419 (G) CETP L0.028, P ¼ 831013 0.147, P ¼ 8310373 L0.024, P ¼ 331012 0.109, P ¼ 331010
rs5880 (G) CETP 0.047, P ¼ 9107 0.307, P ¼ 4310257 L0.048, P ¼ 33108 0.144, P ¼ 6105
rs6859 (G) PVRL2 L0.084, P ¼ 1310101 0.018, P ¼1 106 0.014, P ¼ 6105 0.077, P ¼ 8106
rs103294 (T) LILRB2/LILRA5 0.007, P ¼ 0.12 0.052, P ¼ 431033 0.002, P ¼ 0.61 0.087, P ¼ 6105
rs4465830 (A) ZNF335 0.009, P ¼ 0.06 0.060, P ¼ 431042 L0.053, P ¼ 531036 0.087, P ¼ 4105
Single nucleotide polymorphisms (effect alleles) are those associated with age-related macular degeneration (AMD) risk at a Bonferroni-corrected level of
signiﬁcance (P < 0.05/182 ¼ 0.0003). Beta-coefﬁcients for lipid fractions (low-density lipoprotein cholesterol [LDL-c], high-density lipoprotein cholesterol
[HDL-c], and triglycerides) represent changes in the lipid fraction per additional copy of the effect allele in standard deviation units. Beta-coefﬁcients for
AMD represent log odds ratios (ORs) per additional copy of the effect allele. Boldface indicates association at a genome-wide level of signiﬁcance (P <
5108); italics indicate association at a Bonferroni-corrected level of signiﬁcance. All variants are oriented to the AMD risk-increasing allele.
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In addition to simple look-ups of the genetic associations for the
chosen variants, we also considered the association of genetic risk
scores with AMD risk for variants in the HMGCR and NCP1L1
gene regions. These scores were calculated using 3 and 5 variants,
respectively, that have been identiﬁed to be minimally correlated
(r2 < 0.2) and independently associated with LDL-cholesterol. We
performed an inverse-variance weighted Mendelian randomization
analysis for the effect of LDL-cholesterol on AMD risk using
correlated variants. This is equivalent to testing the association of a
genetic risk score with AMD risk, where the score is weighted by
the conditional associations of the variants with LDL-cholesterol.25
The Mendelian randomization estimates were an odds ratio (OR) of
0.64 (95% conﬁdence interval [CI], 0.42e0.98; P ¼ 0.042) per 1
standard deviation increase in LDL-cholesterol for variants in the
HMGCR gene region and 0.59 (95% CI, 0.32e1.07; P¼ 0.082) for
variants in the NPC1L1 gene region.
Univariable Mendelian Randomization
Univariable Mendelian randomization analyses are conducted using
summarized data on the per allele genetic associations with the risk
factor and with the outcome and the Mendelian Randomization
package for the R statistical software platform (https://cran.r-pro-
ject.org/web/packages/MendelianRandomization/). For each of
HDL-cholesterol, LDL-cholesterol, and triglycerides, we take all
variants associated with the risk factor at a genome-wide level of
signiﬁcance (86 for HDL-cholesterol, 76 for LDL-cholesterol, 51 for
triglycerides). The genetic associations with the outcome for those
variants are regressed on the genetic associations with the risk factor.
Inverse-variance weights are used in the regression model. A
(multiplicative) random-effects model is used in each analysis. For
the inverse-variance weighted method, the intercept in the regression
model is ﬁxed at zero.15 For the MR-Egger method, all genetic as-
sociations are oriented to the risk factoreincreasing allele, and the
intercept is estimated as part of the analysis.17 In the weighted
median method, the same inverse-variance weights are used, and
CIs are constructed using a previously described bootstrapmethod.18
Multivariable Mendelian Randomization
Multivariable Mendelian randomization analyses are conducted
using summarized data. A multivariable weighted regressionanalysis is performed with the genetic associations with the
outcome regressed on the genetic associations with the 3 risk
factors in a single regression model.26 The intercept in this
regression model was ﬁxed at zero. Because the variants are
allowed to be associated with any or all of the risk factors, data
on all of the 185 variants that have associations with the
outcome are included in the analysis. Inverse-variance weights
are used in the regression model. A (multiplicative) random-effects
model is used in each analysis.Results
Genetic Associations of Variants with Disease
Outcomes
We constructed a quantile-quantile plot to compare the chi-square
statistics for the association with AMD risk with the expected
distribution of chi-square statistics under the null for 185 lipid-
related variants in 157 different genetic loci that were associated
at a genome-wide level of signiﬁcance with at least 1 lipid fraction
in a conditional analysis (3 variants: rs188026950, rs2247056, and
rs4332136 were omitted from the analysis because of missing data
for at least 1 disease; none were strongly associated with any
outcome in the available associations; P > 0.05). The plots for
AMD, CAD, and Alzheimer’s disease are provided in Figure 1. In
total, 9 variants were associated with AMD risk at a Bonferroni-
corrected P value (P < 0.05/182 ¼ 0.0003), and 3 variants were
associated with AMD risk at a genome-wide level of signiﬁcance
(P< 5108). This compares with 17 and 5 variants for CAD risk,
and 4 and 1 variants for Alzheimer’s disease risk. A list of variants
associated with AMD risk at a Bonferroni-corrected level of sig-
niﬁcance is provided in Table 1. Similar lists for CAD and
Alzheimer’s disease are provided in Tables S1 and S2 (available
at www.aaojournal.org).
The lipid-related variants with the strongest associations with
AMD risk have a similar strength of statistical association with
disease risk as those variants with the strongest associations with
CAD risk. The tail of the distribution is longer for CAD, with a
greater number of variants associated with CAD risk at
subegenome-wide association study signiﬁcance levels (e.g., 32
variants were associated with AMD risk at P < 0.05, compared
with 72 for CAD risk). However, the sample size for genetic as-
sociations with CAD risk was larger, meaning that true positive3
Figure 1. Quantile-quantile plot of chi-square statistics for associations of lipid-related variants with disease outcomes. Chi-square association statistics for
182 genetic variants (3 variants, rs188026950, rs2247056, and rs4332136, were omitted because of missing data) against expected values of a chi-square
distribution under the null hypothesis of no association of the variants with disease risk. The line represents the null hypothesis. The APOE variant
(rs10401969) is omitted from the plot for Alzheimer’s disease; its observed chi-square statistic was 435.8.
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make direct comparisons for the total number of lipid-related
predictors of AMD and CAD problematic. In contrast, the asso-
ciations of lipid-related variants with Alzheimer’s disease are
stronger than would be expected due to chance alone, but not
considerably so (19 variants were associated with Alzheimer’s
disease risk at P < 0.05; 9 associations would be expected due to
chance alone).
Genetic Proxies for Lipid Therapy
From this list of 185 variants, we considered variants in the PCSK9
gene region that can be considered as a proxy for PCSK9 in-
hibitors,27 in the HMGCR gene region (proxy for statin
treatment28), in the NPC1L1 gene region (proxy for ezetimibe
and related NPC1L1 inhibitors29), in the LPA and APOC3 gene
regions (treatments to lower lipoprotein(a)30 and inhibit
apolipoprotein C-III31 are in development), in the CETP gene
region (proxy for anacetrapib and related CETP inhibitors32), and
in the APOE gene region (a potential target for pharmacologic
intervention). Associations of these variants with AMD risk,
CAD risk, and Alzheimer’s disease risk are provided in Table 2.
Although none of the associations with CAD risk reached sta-
tistical signiﬁcance after correction for multiple testing, variants in
all the gene regions apart from the CETP region were at least
nominally associated with CAD risk (P < 0.05). This corresponds
to what is known from successful randomized trials of reducing
CAD risk with statin treatment,33 PCSK9 inhibitors34 and
ezetimibe,29 and unsuccessful trials of CETP inhibitors.35 In
contrast, after accounting for multiple testing, variants in the
APOE and CETP gene regions were associated with AMD risk,
suggesting that lowering APOE may decrease AMD risk and that
inhibiting CETP to increase HDL-cholesterol levels may increase
AMD risk. In addition, the HMGCR variant was associated with
AMD risk at a nominal level of signiﬁcance (P ¼ 0.01), suggesting
that reducing LDL-cholesterol via statin medication may increase
AMD risk. This is in contrast to initial reports suggesting a possible
protective effect of statin use for AMD,36 although a later larger
and more detailed analysis reported different directions of
association (both protective and deleterious) for statin use on
stratiﬁcation for baseline lipid concentration and AMD status
(exudative vs. nonexudative).37 However, individuals who take4statins typically would have elevated concentrations of LDL-
cholesterol before statin prescription, making interpretation of
previous observational studies difﬁcult, and the question of the
effect of statins on AMD initiation or progression remains unre-
solved.38 We attempted to reﬁne the ﬁndings for variants in the
HMGCR and NPC1L1 gene regions using genetic risk scores
based on multiple variants in each gene region that have
previously been identiﬁed39; similar results were obtained for the
associations of these scores with AMD risk (P ¼ 0.042 for
HMGCR, P ¼ 0.082 for NPC1L1). We also considered the
associations with AMD risk of 2 further variants in the APOE
gene region40: rs7412, the T allele of which tags the APOE ε2
variant (per allele OR, 1.59; P ¼ 21042), and rs429358, the C
allele of which tags the APOE ε4 variant (per allele OR, 1.12;
P ¼ 8106). Alzheimer’s disease was strongly associated with
variants in the APOE gene region, but was not associated with
variants in any of the other gene regions considered.
Univariable Mendelian Randomization
We performed univariable Mendelian randomization for each of
the lipid fractions in turn. For each analysis, we included all genetic
variants that were associated with that lipid fraction at a genome-
wide level of signiﬁcance (P < 5108). This resulted in up to
76 variants being included in the analysis for LDL-cholesterol, 86
variants for HDL-cholesterol, and 51 variants for triglycerides. In
addition to the standard method for Mendelian randomization using
summarized data (the inverse-variance weighted method41), which
assumes that all genetic variants are valid instrumental variables
(i.e., not associated with confounders and only associated with
the outcome via the lipid fraction under analysis42), we also
performed the MR-Egger method17 (which allows variants to
have pleiotropic effects on the outcome not via the risk factor
under analysis, provided that such effects are independent of
instrument strength), and the weighted median method18 (which
allows some variants not to be valid instruments, provided that at
least 50% of the variants by weight are valid instruments). The
inverse-variance weighted method tests for an association be-
tween genetic predictors of the exposure and the outcome, whereas
the MR-Egger method tests for a dose-response relationship in
those associations, and the weighted median method assesses
whether the associations with the outcome are evidenced across the
Table 2. Genetic Proxies for Lipid Therapy and Their Associations with Disease Outcomes
Single Nucleotide
Polymorphism Gene Region
Association of Variant with. (Beta Coefﬁcient and P Value)
LDL-c HDL-c Triglycerides AMD Risk CAD Risk ALZ Risk
rs12067569 (G) PCSK9* L0.089 0.007 0.005 0.020 0.048 0.048
P ¼ 931011 P ¼ 0.33 P ¼ 0.52 P ¼ 0.61 P ¼ 0.04 P ¼ 0.25
rs7703051 (C) HMGCR L0.073 0.002 0.006 0.044 0.030 0.015
P ¼ 531085 P ¼ 0.56 P ¼ 0.09 P ¼ 0.010 P ¼ 0.002 P ¼ 0.37
rs2297374 (T) LPA L0.032 0.006 0.009 0.026 0.038 0.014
P ¼ 631018 P ¼ 0.11 P ¼ 0.008 P ¼ 0.14 P ¼ 8105 P ¼ 0.40
rs1564348 (T) LPA L0.048 0.008 0.016 0.026 0.030 0.007
P ¼ 331022 P ¼ 0.10 P ¼ 0.0003 P ¼ 0.28 P ¼ 0.022 P ¼ 0.74
rs2073547 (A) NPC1L1 L0.048 0.005 0.015 0.021 0.021 0.025
P ¼ 531023 P ¼ 0.28 P ¼ 0.0009 P ¼ 0.32 P ¼ 0.08 P ¼ 0.24
rs217386 (A) NPC1L1 L0.036 0.001 0.010 0.031 0.022 0.005
P ¼ 831022 P ¼ 0.71 P ¼ 0.003 P ¼ 0.08 P ¼ 0.029 P ¼ 0.77
rs10790162 (A) APOC3 0.076 L0.095 0.230 0.042 0.043 0.046
P ¼ 331026 P ¼ 331046 P ¼ 1310276 P ¼ 0.16 P ¼ 0.004 P ¼ 0.13
rs603446 (C) APOC3 0.009 0.002 0.050 0.006 0.015 0.032
P ¼ 0.013 P ¼ 0.60 P ¼ 231050 P ¼ 0.73 P ¼ 0.12 P ¼ 0.05
rs9989419 (G) CETP L0.028 0.147 L0.024 0.109 0.009 0.008
P ¼ 831013 P ¼ 8310373 P ¼ 331012 P ¼ 331010 P ¼ 0.36 P ¼ 0.63
rs5880 (G) CETP 0.047 0.307 L0.048 0.144 0.007 0.027
P ¼ 9107 P ¼ 4310257 P ¼ 33108 P ¼ 6105 P ¼ 0.75 P ¼ 0.52
rs6859 (G) APOE L0.084 0.018 0.014 0.077 0.026 L0.334
P ¼ 1310101 P ¼ 1106 P ¼ 6105 P ¼ 8106 P ¼ 0.010 P ¼ 931097
rs7254892 (A) APOE L0.485 0.053 0.124 0.063 0.078 0.250
P ¼ 8310365 P ¼ 3106 P ¼ 431031 P ¼ 0.19 P ¼ 0.009 P ¼ 1105
Single nucleotide polymorphisms (effect alleles) are the lead variants in each gene region taken from the Global Lipids Genetics Consortium. Associations
with lipid fractions (low-density lipoprotein cholesterol [LDL-c], high-density lipoprotein cholesterol [HDL-c]. and triglycerides) are in standard deviation
units. Associations with disease outcomes (age-related macular degeneration [AMD], coronary artery disease [CAD], Alzheimer’s disease [ALZ]) are log odds
ratios from logistic regression analyses. Boldface indicates association at a genome-wide level of signiﬁcance (P < 5108); italics indicate association at a
Bonferroni-corrected level of signiﬁcance (P < 0.05/182 ¼ 0.0003). All variants are orientated to the AMD risk-increasing allele.
*The original lead variant reported for the PCSK9 gene region (rs188026950) was not available in the AMD, CAD, or ALZ consortium data.
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associations are presented graphically in Figure S1 (available at
www.aaojournal.org).
By using the standard inverse-variance weighted method, all 3
lipid fractions are causally associated with CAD risk. The associ-
ation for LDL-cholesterol is evidenced by all 3 univariable
methods, whereas the association for HDL-cholesterol is null in the
MR-Egger and weighted median methods, suggesting that the as-
sociation in the inverse-variance weighted method may be due to
pleiotropy. In contrast, although there is little evidence from uni-
variable Mendelian randomization analyses that LDL-cholesterol
or triglycerides inﬂuence AMD risk, the inverse-variance
weighted and weighted median methods suggest a causal effect
of HDL-cholesterol on AMD risk, with estimates implying a
detrimental effect of increasing HDL-cholesterol on AMD risk.
The MR-Egger estimate was somewhat attenuated and compatible
with the null, although there was no clear evidence for directional
pleiotropy in the MR-Egger intercept test (P ¼ 0.28). There was
evidence for substantial heterogeneity in the single nucleotide
polymorphismespeciﬁc causal estimates for HDL-cholesterol,
with Cochran’s heterogeneity test statistic taking a value of Q ¼
330.3 (85 degrees of freedom; P < 0.0001).43 Visual inspection of
Figure 2 demonstrates this heterogeneity, with most HDL-
cholesteroleincreasing genetic variants being associated with
increased AMD risk, but some variants showing the opposite
direction of association. The 2 variants that are the clearest
outliers in their associations with HDL-cholesterol and AMD risk
are rs1532085 and rs261342, both located in the LIPC gene region
(Table 1), which are associated with decreased HDL-cholesterolconcentrations and increased AMD risk. Cook’s distance (a mea-
sure of inﬂuence in a regression analysis) was less than 0.15 for all
variants except for those in the CETP and LIPC gene regions. The
inverse-variance weighted method for HDL-cholesterol omitting
variants in the CETP and LIPC gene regions from the analysis gave
a causal estimate of 1.34 (95% CI, 1.14e1.58), suggesting that the
positive Mendelian randomization ﬁnding is not driven solely by a
small number of variants. In a sensitivity analysis, we performed 1
million iterations in which we removed 30% of genetic variants
(28/86) at random from the Mendelian randomization analysis for
HDL-cholesterol and re-ran the analysis using the remaining 60
variants; 96% of the iterations reported a positive causal estimate
(Fig S2, available at www.aaojournal.org). For Alzheimer’s
disease, although the univariable Mendelian randomization
analyses including all variants suggested a causal effect of LDL-
cholesterol on Alzheimer’s disease risk, all associations attenu-
ated to the null when the APOE variants were omitted from the
analysis.
Multivariable Mendelian Randomization
We performed multivariable Mendelian randomization for all 3
lipid fractions in a single analysis model (Table 4). Multivariable
Mendelian randomization allows genetic variants to have
pleiotropic effects, but only on other variables included in the
model (so a variant is allowed to inﬂuence multiple lipid
fractions, so long as any association with the outcome is via a
lipid fraction).19 The analyses each include all of the 185
variants for which data are available on associations with the5
Table 3. Results from Univariable Mendelian Randomization on Each Lipid Fraction in Turn
Lipid Fraction Method AMD CAD ALZ*
LDL-c Inverse-variance weighted 0.94 (0.82e1.09) 1.53 (1.40e1.67) 1.02 (0.93e1.12)
P ¼ 0.41 P ¼ 21014 P ¼ 0.67
MR-Egger 0.88 (0.70e1.11) 1.61 (1.39e1.85) 1.05 (0.89e1.24)
P ¼ 0.28 P ¼ 9109 P ¼ 0.56
Weighted median 0.91 (0.80e1.02) 1.59 (1.45e1.73) 1.04 (0.92e1.18)
P ¼ 0.11 P ¼ 31025 P ¼ 0.49
HDL-c Inverse-variance weighted 1.22 (1.03e1.44) 0.85 (0.76e0.95) 0.98 (0.88e1.09)
P ¼ 0.02 P ¼ 0.005 P ¼ 0.76
MR-Egger 1.08 (0.82e1.42) 1.10 (0.93e1.31) 0.91 (0.76e1.09)
P ¼ 0.58 P ¼ 0.26 P ¼ 0.32
Weighted median 1.46 (1.23e1.74) 0.95 (0.87e1.05) 1.05 (0.92e1.20)
P ¼ 3105 P ¼ 0.32 P ¼ 0.46
Triglycerides Inverse-variance weighted 0.85 (0.67e1.07) 1.30 (1.17e1.45) 0.98 (0.88e1.09)
P ¼ 0.16 P ¼ 1105 P ¼ 0.68
MR-Egger 1.31 (0.93e1.86) 1.09 (0.93e1.29) 1.06 (0.89e1.27)
P ¼ 0.13 P ¼ 0.31 P ¼ 0.51
Weighted median 1.13 (0.95e1.34) 1.25 (1.12e1.38) 1.00 (0.85e1.17)
P ¼ 0.17 P ¼ 3105 P ¼ 0.97
ALZ ¼ Alzheimer’s disease; AMD ¼ age-related macular degeneration; CAD ¼ coronary artery disease; HDL-c ¼ high-density lipoprotein cholesterol;
LDL-c ¼ low-density lipoprotein cholesterol; MR ¼ Mendelian randomization.
Estimates are odds ratios (95% conﬁdence intervals) for the effect of a 1 standard deviation increase in the lipid fraction. All genetic variants that are
associated with the lipid fraction at a genome-wide level of signiﬁcance (P < 5108) are included in the analysis for that lipid fraction.
*Variants from the APOE gene region were omitted from analyses for Alzheimer’s disease because they dominated the results.
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univariable analyses, except that only LDL-cholesterol and tri-
glycerides (and not HDL-cholesterol) were associated with CAD
risk. Only HDL-cholesterol was associated with AMD risk. None
of the 3 lipid fractions were associated with Alzheimer’s risk (once
variants in the APOE gene region were omitted from the analysis).
We plotted ﬁtted values from the multivariable Mendelian
randomization analysis models against their associations with the
outcome in Figure 2. The ﬁtted values represent the expected
associations of the genetic variants with the outcome based on
their associations with the lipid fractions alone. In the absence ofFigure 2. Observed versus expected genetic associations with outcome from
outcome for each genetic variant (y-axis) are plotted against the expected assoc
(ﬁtted values from the multivariable Mendelian randomization regression model
disease; AMD ¼ age-related macular degeneration; CHD ¼ coronary heart dis
6heterogeneity and pleiotropy, and with inﬁnitely large sample
sizes, these graphs would be straight lines through the origin.
For CAD risk, correlation between the observed and expected
associations with the outcome in Figure 2 is apparent, and the
multivariable Mendelian randomization model explains a large
proportion of the variance in the observed associations with the
outcome (R2 ¼ 42.4%). In contrast, for AMD risk, the model
explains 5.2% of the variance, and for Alzheimer’s disease risk,
1.0%, no more than would be expected by chance alone. Genetic
predictors of lipid fractions are clearly individually associated
with AMD risk, but overall the associations withmultivariable Mendelian randomization analysis. Associations with the
iations with the outcome based on the associations with the lipid fractions
; x-axis). Each point represents a single genetic variant. ALZ ¼ Alzheimer’s
ease.
Table 4. Results from Multivariable Mendelian Randomization on All Lipid Fractions in Single Model
Lipid Fraction Method AMD CAD ALZ*
LDL-c Multivariable MR 0.96 (0.83e1.11) 1.48 (1.36e1.61) 1.02 (0.93e1.14)
P ¼ 0.55 P ¼ 21021 P ¼ 0.58
HDL-c Multivariable MR 1.18 (1.01e1.38) 0.93 (0.85e1.02) 0.94 (0.84e1.05)
P ¼ 0.03 P ¼ 0.13 P ¼ 0.25
Triglycerides Multivariable MR 1.04 (0.77e1.12) 1.16 (1.04e1.29) 0.93 (0.82e1.07)
P ¼ 0.44 P ¼ 0.009 P ¼ 0.31
ALZ ¼ Alzheimer’s disease; AMD ¼ age-related macular degeneration; CAD ¼ coronary artery disease; HDL-c ¼ high-density lipoprotein cholesterol;
LDL-c ¼ low-density lipoprotein cholesterol; MR ¼ Mendelian randomization.
Estimates are odds ratios (95% conﬁdence intervals) for the effect of a 1 standard deviation increase in the lipid fraction. All genetic variants that are
associated with at least 1 lipid fraction at a genome-wide level of signiﬁcance (P < 5108) are included in the analyses.
*Variants from the APOE gene region were omitted from analyses for Alzheimer’s disease because they dominated the results.
Burgess and Davey Smith  Mendelian Randomization of HDL-C and AMD RiskLDL-cholesterol, HDL-cholesterol, and triglycerides are far less
predictive of AMD risk than they are for CAD risk.Discussion
In this article, we have analyzed a comprehensive set of
variants that have been demonstrated to be associated with
at least 1 lipid fraction among LDL-cholesterol, HDL-
cholesterol, or triglycerides at a genome-wide level of sig-
niﬁcance. We have examined the associations of these
variants with AMD risk, both considering individual vari-
ants that are proxies for lipid therapy or strongly associated
with AMD risk, and considering all variants associated with
a particular lipid fraction and their association with AMD
risk in a Mendelian randomization framework. Two-sample
Mendelian randomization was performed using summary
statistics on genetic associations with the risk factor and
with the disease outcome taken from separate datasets. The
standard inverse-varianceeweighted analysis is equivalent
to considering whether a genetic risk score, weighted by its
associations with the risk factor estimated in the ﬁrst data
set, is associated with the outcome in the second data set.25
We also considered methods that make alternative
assumptions to the standard Mendelian randomization
method, including the MR-Egger, weighted median, and
multivariable Mendelian randomization methods.
Finally, in addition to AMD, we also considered CAD
and Alzheimer’s disease as outcomes. Coronary artery dis-
ease represents a positive control, which is expected to be
associated with lipid-related variants, whereas Alzheimer’s
disease represents a negative control, because no association
with lipid-related variants (aside from variants in the APOE
gene region) has been previously demonstrated. Although
the 185 lipid-related variants were more associated with
Alzheimer’s disease than would be expected by chance
alone, calling into question whether Alzheimer’s disease is
truly a negative control for lipid fractions, it is perhaps
unreasonable to assume that so many variants associated
with lipid concentrations should all have null associations
with Alzheimer’s disease, particularly because several of the
variants are associated with other potential risk factors for
Alzheimer’s disease. However, there was no robustassociation of any lipid fraction with Alzheimer’s disease in
any of the Mendelian randomization analyses, suggesting
that there is no consistent relationship between lipid-related
variants and Alzheimer’s disease, and that associations of
individual variants with Alzheimer’s disease are unlikely to
be driven by lipids.
We observed that variants in gene regions linked with
HDL-cholesterolerelated mechanisms were associated with
AMD risk. This was evident through associations with vari-
ants in the CETP gene region, which can be considered as
proxies forCETP inhibition.CETP inhibition increases HDL-
cholesterol levels, and the CETP variants associated with
increases in HDL-cholesterol concentrations also were asso-
ciated with increased AMD risk. In addition, variants in the
APOE gene region that also increase HDL-cholesterol were
also associated with increased AMD risk. Although variants
in the CETP and APOE gene regions are also associated with
LDL-cholesterol levels, associations with AMD risk were
stronger for variants in the CETP gene region, in line with the
associations of the variants with HDL-cholesterol (stronger
for the CETP variants) and the opposite of the associations of
the variants with LDL-cholesterol (stronger for the APOE
variants). Associations of HDL-cholesterol with AMD risk
were observed in the Mendelian randomization analyses,
speciﬁcally using the inverse-variance weighted, weighted
median, and multivariable Mendelian randomization
methods. Although the association in the MR-Egger method
was somewhat attenuated and compatible with the null, there
was no clear evidence of directional pleiotropy in the MR-
Egger analysis. However, there was substantial heterogene-
ity in these analyses, suggesting that not all mechanisms for
increasing HDL-cholesterol would be expected to increase
AMD risk uniformly. For example, the causal estimate using
the CETP variant rs5880 is an OR of 2.10 (95% CI,
1.30e3.39) per standard deviation increase in HDL-
cholesterol, larger than the causal estimate of 1.22 (95% CI,
1.03e1.44) from theMendelian randomization analysis using
all HDL-cholesteroleassociated variants. Variants in the
LIPC gene region that were strongly associated with AMD
risk had a direction of association with HDL-cholesterol
opposite that of other variants. Overall, the level of evi-
dence from Mendelian randomization for a causal role of
long-term elevated levels of HDL-cholesterol in increasing7
Ophthalmology Volume -, Number -, Month 2017AMD risk is not as strong as that for LDL-cholesterol in CAD,
but there is broadly consistent evidence for a causal role
across a range of analysis methods.
Study Strengths and Limitations
An advantage of the Mendelian randomization framework
using multiple genetic variants is the ability to consider
multiple independent genetic variants in different locations
on the genome that each inﬂuence HDL-cholesterol and
their associations with AMD risk. A disadvantage of the use
of multiple variants is that the analysis does not point to a
single mechanism as causal for AMD risk, although the
CETP gene region suggests 1 potential mechanism. A
search of the U.S.-based clinicaltrials.gov and the EU
Clinical Trials Register did not reveal any trials of CETP
inhibition that measured AMD as an outcome. The
assumption of Mendelian randomization that all genetic
variants are valid instrumental variables is unlikely to hold
in this case. We were able to consider 3 separate methods
that allow for weaker assumptions: the MR-Egger method
that allows for unmeasured pleiotropy; the weighted median
method, which is robust to the inﬂuence of outliers; and the
multivariable Mendelian randomization method that allows
for measured pleiotropy. These methods generally sup-
ported a causal effect of HDL-cholesterol on AMD risk. In
addition, the negative control analysis of Alzheimer’s dis-
ease did not suggest that any of the lipid fractions were
causal for Alzheimer’s disease, meaning that pleiotropy did
not lead to false-positive ﬁndings in this case.
The risk factor considered in this investigation was circu-
lating levels of serum lipid concentrations. It seems that AMD-
related lipid deposition is inﬂuenced both by circulating levels
(that underlie systemic processes such as atherosclerosis) and
by retina-speciﬁc processes.44 Intracellular lipid concentrations
or lipid concentrations localized to the retina would be more
relevant measurements for understanding AMD risk, and
heterogeneity in the genetic associations (even different
directions of association with AMD risk) may result from
discordancy between genetic associations with circulating
and intracellular lipid concentrations. Many of the lipid-
related genetic variants we use, identiﬁed from studies of
circulating lipids, have been investigated as speciﬁc risk in-
dicators in AMD.45 Molecular genetic variation around
particular genes could generate effects on retinal lipid
processing that are not reﬂected in, or indeed could be the
reverse of, effects on circulating lipids. Speculatively, such
mechanisms could explain the opposite associations of CETP
and LIPC variants with AMD in relation to their association
with circulating HDL-cholesterol. The local retinal functional
consequences of themolecular genetic variationwe examine in
this study are not well deﬁned and certainly constitute an
important area for future research.44,45
This analysis used state-of-the-art methods for Mendelian
randomization and the largest currently available sources of
data on genetic associations with lipid fractions and with
AMD risk to address the question of causality as compre-
hensively as possible, but clearly will beneﬁt from increased
functional understanding of genetic variants from which we
leverage explanatory power.8In conclusion, some genetic evidence suggests that HDL-
cholesterol is a causal risk factor for AMD risk and that
increasing HDL-cholesterol (in particular via inhibition of
CETP and lowering of APOE) will lead to increased risk of
AMD. Studies developing pharmacologic interventions for
lipid therapy should monitor AMD events as a potential
adverse outcome, particularly for drugs designed to increase
HDL-cholesterol levels and for studies of individuals at a
high risk of developing AMD.References
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